Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New embryo genetic test aims to cut miscarriages and birth defects

NCT ID NCT07533630

Knowledge-focused Sponsor: Reproductive & Genetic Hospital of CITIC-Xiangya Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test an upgraded genetic test (PGT-A upgrade) on embryos from 1,700 IVF patients across multiple countries. The test looks for a wider range of chromosomal issues than standard tests. Researchers hope this will help select healthier embryos, reducing the chance of miscarriage and birth defects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PGT-A upgrade genetic test
What this could lead to
If successful, this could improve embryo selection in IVF, potentially lowering miscarriage and birth defect rates.
What could go wrong
This is an observational study, not a treatment trial. It may not directly improve pregnancy outcomes, and results may take years to apply clinically.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,700 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study is a cross-sectional study with a two-sided test and α = 0.05. Based on the analysis of existing data from previous PGT-A upgrade studies performed in 2PN embryos, the total incidence rate (p) of microdeletion/microduplication, heteroploidy, and UPD/LOH in euploid embryos is estimated to be 2.0%, with a margin of error (δ) of 0.005. The required number of euploid embryos is 3,012, and the calculation formula is provided below. Given that the euploidy rate is approximately 50%, a total of 6,024 embryos tested by PGT-A upgrade needs to be enrolled. Considering the potential dropout risk (10%), 6,694 embryos from two pronuclei (PN) are included. All embryos from 0PN/1PN/3PN are included.

Ages

20 to 46 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: (1) Any one of the following conditions being met is sufficient: 1. advanced maternal age (AMA, age ≥35 years), 2. recurrent implantation failure (RIF), 3. recurrent miscarriage (RM), 4. severe male factor (SMF). (2) And at least one blastocyst is available. Exclusion Criteria: 1. Couples undergoing PGT-SR due to chromosomal structural abnormalities carried by either one or both members, such as balanced translocations, Robertsonian translocations, inversions, complex chromosomal rearrangements, and pathogenic microdeletions or microduplications; 2. Couples undergoing PGT-M; 3. Conditions with established impact on uterine morphology or endometrial receptivity, including untreated uterine malformations (septate uterus, unicornuate uterus, didelphic uterus, etc.) and untreated hydrosalpinx; 4. Embryos coming from oocyte or sperm (gametes) donation; 5. Individuals with contraindications to pregnancy or assisted reproduction technology.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infertility assisted reproductive technology are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertility assisted reproductive technology

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Biocódices

    Buenos Aires, Argentina

  • CITIC-Xiangya Reproductive & Genetic Hospital

    Changsha, Hunan, China

  • First People's Hospital of Yunnan Province

    Kunming, Yunnan, China

  • Institute Bernabéu

    Alicante, Spain

  • Miracle

    Daegu, South Korea

  • Nanjing Women and Children's Healthcare Hospital

    Nanjing, Jiangsu, China

  • Thomson Hospital

    Petaling Jaya, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.